Benefits and safety of IRon supplementation with MAlaria chemoprevention to children in Malawi (IRMA) - A randomised controlled trial
- Conditions
- AnaemiaMalariaImpaired child cognitive developmentStuntingDiarrhoeaIron DeficiencyBlood - AnaemiaInfection - Other infectious diseasesDiet and Nutrition - Other diet and nutrition disorders
- Registration Number
- ACTRN12620000386932
- Lead Sponsor
- College of Medicine, University of Malawi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 2168
1.Infants aged 6 months (+/- 14 days) at the time of randomisation
2.Has a legally acceptable guardian/representative capable of understanding the informed consent document and providing consent on the participant’s behalf
1.Severe anaemia (Hb<7g/dL) or
2.Current infective illness with fever (respiratory infection, diarrhoea, malaria); however, children will be screened again after recovery and recruited as long as they meet the age eligibility criteria at second screening
3.Severe malnutrition (weight-for-length z-score<-3);
4.Established diagnosis of haemoglobinopathy (e.g. sickle cell disease, beta thalassaemia major, HbE-beta thalassaemia).
5.Legal guardian unwilling or unable to provide written informed consent
6.Known congenital anomaly, developmental disorder or severe developmental delay
7.Children with physical or behavioural problems that will make it impossible to test the child
8.Children of multiple birth e.g. twin, triplets etc.
9.Currently consuming MNPs e.g. from the National MNP programme
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive development: assessed by the Bayley® 3rd Edition (Bayley-III) Cognitive Composite Score (CogCS)[End Intervention period (6 months post recruitment)]
- Secondary Outcome Measures
Name Time Method